Share on StockTwits

Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 1,165 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $11.54, for a total value of $13,444.10. Following the completion of the transaction, the insider now directly owns 2,121,526 shares of the company’s stock, valued at approximately $24,482,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eleven Biotherapeutics (NASDAQ:EBIO) traded up 1.86% on Monday, hitting $11.50. 618 shares of the company’s stock traded hands. Eleven Biotherapeutics has a 52-week low of $9.502 and a 52-week high of $19.333. The stock has a 50-day moving average of $11.84 and a 200-day moving average of $12.95. The company’s market cap is $177.0 million.

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.

Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.